Four Vanderbilt inventions earn patent protection in December 2013

Four Vanderbilt technologies earned patent protection from the USPTO in December, bringing the total number of patents assigned to Vanderbilt to 23 for the first half of FY14. The technologies include a new method for tumor detection, developed by Ray Mernaugh in the Biochemistry Department and Dennis Hallahan, formerly at VUMC; a new system for point-based rigid registration with anisotropic weighting developed by John Michael Fitzpatrick in the Department of Electrical Engineering and Computer Science; GBS toxin receptor compositions developed by Carl Hellerqvist from the Biochemistry Department and Changlin Fu; and a new compound that may be used to treat various neurological and psychiatric disorders that was developed by P. Jeffrey Conn and others at the Vanderbilt Center for Neuroscience Drug Discovery.  Click the links below to read more.

  PAT. NO.   Title
  8,617,521   Phage antibodies to radiation-inducible neoantigens
  8,615,127   System and method for point-based rigid registration with anisotropic weighting
  8,609,614   GBS toxin receptor compositions and methods of use
  8,598,345   Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same